Allostery Investments LP
- SEC CIK
- 0001978599
- Latest filing
- Nov 14, 2025
The latest 13F from Allostery Investments LP covers Q3 2025 (filed Nov 14, 2025) and reports no long positions. Livermore has 4 filings on Form 13F from this institution, going back to Q4 2024.
What changed in Q3 2025
Share counts compared with Q2 2025: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.
- New
- 0
- Added
- 0
- Reduced
- 0
- Sold out
- 20
- Est. −$7.85M
Top 5 holdings
Share of this quarter's portfolio value
This filing reports no long positions.
Biggest buys
New and added positions, by estimated amount bought
None this quarter.
Largest weight increases
New and added positions, by percentage points of the portfolio gained
None this quarter.
Biggest sells
Reduced and sold-out positions, by estimated amount sold
Largest weight decreases
Reduced and sold-out positions, by percentage points of the portfolio lost
Metrics
13F metrics for Q3 2025, computed only from the numbers in the filings. Definitions below.
- Portfolio value
- $0
- −$7.85M (−100.0%) vs. prior quarter
- Positions
- 0
- −20 vs. prior quarter
- Top 10 concentration
- –
- Top 10 as share of value
- Turnover
- 0.0%
- Q3 2025, one quarter
- Average holding period
- –
- Weighted by value
How these are calculated
- Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
- Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
- Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
- Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q4 2024), so positions held before then are understated.
13F filings by quarter
4 quarters, going back to Q4 2024. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.
Peak $69.3M (Q1 2025)
| Quarter | Filed | Positions | Value | Top 3 holdings | Changes | Filing |
|---|---|---|---|---|---|---|
| Q3 2025 | Nov 14, 2025 | 0 | $0 | – | vs. Q2 2025 | SEC |
| Q2 2025 | Aug 14, 2025 | 20 | $7.85M | ABVXAKROAMLX | vs. Q1 2025 | SEC |
| Q1 2025 | May 15, 2025 | 41 | $69.3M | ABVXCNTAKALV | vs. Q4 2024 | SEC |
| Q4 2024 | Feb 14, 2025 | 30 | $50.9M | CNTAEOLSAPGE | – | SEC |
13D and 13G filings
Companies where Allostery Investments LP reports owning 5% or more on Schedule 13D or 13G, and its latest filings.
Current stakes of 5% or more
Allostery Investments LP does not currently report owning 5% or more of any company.
Latest filings
4 filings on file made by Allostery Investments LP or listing it as a reporting person, newest first.
| Company | Filed (ET) | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| AVTXAvalo Therapeutics, Inc. | Nov 14, 2024 | 13G/AOld format | – | – | – | SEC |
| ORKAOruka Therapeutics, Inc. | Nov 14, 2024 | 13G/AOld format | – | – | – | SEC |
| AVTXAvalo Therapeutics, Inc. | May 13, 2024 | 13GOld format | – | New | – | SEC |
| ORKAOruka Therapeutics, Inc. | Apr 15, 2024 | 13GOld format | – | New | – | SEC |